T-Therapeutics Ltd, a biotechnology company developing soluble T cell receptor (TCR) therapeutics, has appointed Theodora Harold as chief executive officer, succeeding founder and CEO Allan Bradley. Professor Bradley will become chief scientific officer to oversee the scientific development of the company’s product candidates. Ms Harold has over 25 years’ experience in the biotech sector, raising capital for many companies and driving business development deals. Most recently she was CEO of Crescendo Biologics. T-Therapeutics raised $60 million in a Series A financing at the end of 2023 and launched a platform which has been used to generate a pipeline of TCR therapeutics for cancer indications as well as inflammatory disorders.
T-Therapeutics announced the appointments on 10 March 2025.
Copyright 2025 Evernow Publishing Ltd.